S17 Ep26: Emerging Targets, Second-Line Standards, and Molecular Subtyping Signal a New Era in SCLC Care: With Jacob Sands, MD
In today’s episode, we spoke with Jacob Sands, MD. Dr Sands is the associate chief of the Lowe Center for Thoracic Oncology, Oncology Medical Director of the International Patient Center, and physician at Dana-Farber Cancer Institute, as well as an assistant professor at Harvard Medical School in Boston, Massachusetts.
In our exclusive interview, Dr Sands discussed the rapidly evolving treatment landscape for small cell lung cancer (SCLC), emphasizing both the progress made with immunotherapy and the ongoing challenges associated with this aggressive disease. He noted that outcomes now vary…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.